• Valemetostat and Dual EZH1/2 Inhibition in ATL

  2026-09-28

  This 2022 review explains why targeting both EZH1 and EZH2 may overcome compensatory epigenetic activity in adult T-cell leukemia/lymphoma (ATL), and summarizes the evidence behind valemetostat’s approval in Japan. Its main clinical signal was an overall response rate of 48% in a small, single-arm phase II study of relapsed or refractory ATL, supporting further evaluation while leaving comparative efficacy and longer-term outcomes unresolved.

• HOXC8 Suppresses CASP1-Driven Pyroptosis in Lung Cancer

  2026-09-27

  The study links HOXC8 overexpression in non-small cell lung cancer to transcriptional repression of CASP1, showing that HOXC8 depletion can trigger caspase-1- and gasdermin D-dependent pyroptotic death. Its mechanistic model implicates HDAC1/2 recruitment to the CASP1 promoter and suggests that this regulatory axis contributes to lung tumorigenesis.

• Mouse Tissue Lysis Kit K1038: Workflow and QC

  2026-09-26

  The Mouse Tissue Lysis Kit (K1038) prepares tissue lysate for direct PCR-based genotyping, avoiding a separate genomic DNA extraction and purification step. It is intended for research workflows, not diagnostic, clinical, or medical testing; consult the kit instructions for exact sample amounts and digestion conditions.

• Colon-Targeted Cisplatin/SPION Microgels for Cancer

  2026-09-25

  The study develops an orally administered, sequential delivery system that combines dextran microgels with cisplatin- and SPION-loaded lipid nanoparticles to concentrate treatment in the colon. Its key contribution is coordinating gastrointestinal protection, colon-triggered release, folate-receptor-associated uptake, and magnetic hyperthermia in one preclinical platform.

• Aztreonam in Resistance-Era Assay Design

  2026-09-25

  Aztreonam is a monocyclic β-lactam antibiotic whose focused activity makes it useful for investigating Gram-negative bacterial susceptibility. This article connects its mechanism and handling to a large European resistance study, showing how to design more informative assays without treating cefiderocol findings as aztreonam evidence.

• Toremifene Citrate: From ER Mechanism to Translation

  2026-09-24

  Toremifene Citrate offers translational researchers a way to interrogate estrogen receptor biology across binding, cell-based response, and clinical context. This article explains how to interpret its reported activity, design more informative experiments, and avoid overextending preclinical findings.

• Deferasirox in Iron-Dependent Cancer Assays

  2026-09-24

  Deferasirox is an oral iron chelator that can help researchers probe how iron availability shapes cell stress and ferroptosis—not a validated HCC therapy. This workflow frames it as a mechanistic perturbation, with practical controls to distinguish iron depletion from ROS-related effects and treatment toxicity.

• MK-8745: A Potent Aurora A Inhibitor

  2026-09-23

  Use MK-8745 to connect Aurora A inhibition with mitotic disruption, apoptosis, and tumor-model questions. This workflow pairs established cell-assay starting conditions with practical guidance for testing whether Aurora A dependence is relevant to high-risk retinoblastoma or other cancer models.

• Chlorambucil: DNA Crosslinking and Assay Design

  2026-09-23

  Chlorambucil is a nitrogen mustard alkylating agent used in chronic lymphocytic leukemia research and treatment contexts. Its DNA crosslinking mechanism requires assay designs that distinguish growth inhibition from actual cell killing.

• PTX3–TLR4/NF-κB Signaling in Femoral Head Necrosis

  2026-09-22

  The reference study identifies a PTX3–TLR4/NF-κB–FGF21 signaling axis that protects against glucocorticoid-induced osteonecrosis of the femoral head by sustaining osteogenesis and limiting apoptosis. Its combination of patient observations, cellular intervention, genetic loss-of-function, pathway blockade, and downstream rescue provides a mechanistic framework for evaluating PTX3-directed strategies while defining important limits for extrapolation to small-molecule pathway inhibitors.

• XAV-939 Workflows for Wnt Pathway Research

  2026-09-22

  XAV-939, also known as NVP-XAV939, provides a practical way to inhibit tankyrase-dependent Wnt/β-catenin signaling in cancer, fibrosis, bone, and neuroinflammation models. This guide translates pathway biology into executable workflows, control strategies, and troubleshooting decisions for reproducible experiments.

• Cleavage-Resistant TREM2 Restores Efferocytosis

  2026-09-21

  Dong et al. report a synthetic cleavage-resistant TREM2 receptor that preserves macrophage efferocytosis despite inflammatory ADAM17 activity. Phosphatidylserine-functionalized lipid nanoparticles deliver CRT mRNA in situ, producing macrophages that reduce apoptotic-cell accumulation and inflammation in mouse models of MASH and atherosclerosis.

• Cy5 Hydrazide: From Carbonyls to Nanocarrier Translation

  2026-09-21

  A translational framework for using Cy5 hydrazide as a carbonyl-reactive fluorescent dye in oxidative stress studies, protein carbonylation labeling, and food-grade nanonutraceutical analytics.

• Live-Dead Cell Staining Kit I: Calcein AM/PI

  2026-09-20

  The Live-Dead Cell Staining Kit I is a Calcein AM/PI staining kit for rapid fluorescence live/dead detection in mammalian cells. Calcein AM reports intracellular esterase activity, while PI reports loss of plasma-membrane exclusion, creating a practical two-channel readout for viability and cytotoxicity studies.

• JWH 133: CB2 Control of Liver Iron Overload

  2026-09-19

  JWH 133 provides a research-focused way to examine CB2 signaling in hepatic iron overload. This article explains how the compound reveals coordinated STAT3/hepcidin and Nrf2/FPN1 mechanisms, while translating the findings into more discriminating cell-based assay strategies.

8654 records 3/577 page Previous Next 12345 下5页 Last page